Bit bio

Bit bio
Bit bio
Elpis Biomed aims to become a leading, global supplier of in vitro cell types for academic research and commercial drug discovery & development purposes. The cells could provide an alternative to the limited supply of primary cells and replace animal studies in other cases. Elpis Biomed’s proprietary technology allows rapid generation of highly mature, differentiated cell types at unmatched purity. The process is scalable with the potential to expand product offering with additional cell-types in the neuro-mesoderm focus area. Initial products will be cortical neurons, oligodendrocytes and skeletal muscle cells to be sold to academic research groups and pharma/biotech customers.
Cambridge
Biotechnology, Commercial, Health Care
Above €25 million
2016
bit.bio/

Articles about Bit bio:

💡 You’re a corporate or investor and looking for startups that are innovating in the same market as Bit bio? We’re happy to assist you with our Startup Sourcing service.